

# Pharma

## Oct-Dec'20 Earnings Preview

### Domestic formulation fails to pick up

#### Quick pointers:

- Q3 India formulations sales failed to attain normalized growth, despite marketing activities returning to pre-COVID levels.
- US sequential growth to be product specific while travel restrictions of FDA officer delay resolution of plants under regulatory issue.
- Emerging markets and ROW growth could rationalize in Q3 after higher growth in Q2, due to clearance of order backlog.

**In our coverage universe, we expect 3QFY21E Revenue/EBITDA/PBT growth of 9%/30%/42% YoY for pharmaceuticals companies whereas Revenue/EBITDA/PBT growth of 22%/28%/32% YoY for diagnostic companies. We assume, 1) India formulations core portfolio growth to be only in mid/lower-single digit for most companies (Ex-ERIS) even after marketing activities and spends reach pre-COVID levels while CIPLA, GNP and CADILA to report double-digit growth on back of COVID led products, 2) US QoQ growth to be company specific with selective products driving growth while specialty products sales to be better and also reached pre-COVID levels, 3) EM's and ROW growth could rationalize after higher growth in Q2 due to clearance of order backlog due to logistic restriction in 1Q, 4) API growth could be in lower single digit on QoQ after fear over import of Chinese API subside, 5) EBITDAM to remain flat QoQ for companies benefitting from COVID products while rest may witness sequential decline of 200-400bps as marketing activities and MRs getting back to normalized level and 6) Diagnostic companies revenue from core biz could see growth of 5-10% YoY while COVID testing benefit to be lower QoQ.**

**Our top picks are LPC, DRRD and ERIS given resolution of US regulatory issues could lead to new launches, launch of key limited competition drugs and strong IPM growth in chronic and Sub-Chronic products.**

#### Key rating/earnings/TP change:

**JUBILANT:** We increase our TP to Rs964 (earlier Rs754) as we increase our estimate for Pharmaceutical segment and LSI segment by 24% and 20% due to expansion in Radio pharmaceutical biz, resolution of Roorkee (Dosage Form) and Nanjangud (API) manufacturing facilities, opportunities towards COVID vaccine and improved volume (LSI). We continue to value Pharmaceutical and LSI segment on EV/EBITDA multiple of 8x and 4x and retain our Accumulate rating.

**We realign our rating for SUNP (to Hold from Buy), IPCA (to Accumulate from Hold), ARBP (to Hold from Accumulate), CIPLA (to Accumulate from Buy) and adjust to our rating structure due to change in their price performance since 2Q/ last company update. However, our TP remains same for all companies mentioned above.**

January 11, 2021

#### Exhibit 1: PL Universe

Companies	Rating	CMP (Rs)	TP (Rs)
Aurobindo Pharma	HOLD	945	920
Cadila Healthcare	Sell	485	357
Cipla	Acc	839	879
Dr. Lal PathLabs	UR	2,407	NA
Dr. Reddy's Laboratories	BUY	5,338	5,975
Eris Lifesciences	BUY	619	671
Glenmark Pharma	Sell	518	449
Indoco Remedies	BUY	325	352
Ipca Laboratories	Acc	2,143	2,413
Jubilant Life Sciences	Acc	929	964
Lupin	BUY	1,039	1,214
Sun Pharmaceutical Ind.	HOLD	621	602
Thyrocare Technologies	UR	970	NA

Source: PL

#### Exhibit 2: Change in Ratings

Companies	Previous	Current
Aurobindo Pharma	Accumulate	HOLD
Cipla	BUY	Accumulate
Ipca Laboratories	HOLD	Accumulate
Sun Pharmaceutical Ind.	BUY	HOLD

Source: PL

### Top Picks

Lupin

Dr. Reddy's Laboratories

Eris Life Science

Surajit Pal

surajitpal@plindia.com | 91-22-66322259

Tausif Shaikh

tausifshaikh@plindia.com | 91-22-66322246

## Top Picks

**LPC-BUY (TP Rs1,212; CMP Rs1,038):** Revival of US business holds key to our assumption with expected resolution of Somerset, Goa and Pithampur (Unit-2) in FY21E-1H22E. LPC to gain from Perrigo's voluntary recall of gAlbuterol for at least few quarters, while approval rate and quality is likely to improve from FY22E with high value and limited competition products like gSpiriva, gEnvarsus and gDulera lined up for US launch and Fostair in EU. We value LPC on 24x (PE) on FY23E EPS of Rs50.5.

**DRRD-BUY (TP Rs5,964; CMP Rs5,337):** DRRD is one of the few companies whose all plants are cleared by USFDA and have strong product pipeline like gCopaxone, gNuvaring, gVascepa, gKuvan and gRevlimid is lined up for FY22-23E. Its India formulations are also expected to outperform the IPM with fading concerns on COVID. We assume 19% EPS CAGR over FY21-23E. We value DRRD on 24x (PE) of FY23E and include gRevlimid benefit of Rs262/share (assigning 1x(PE) using NPV).

**ERIS-BUY (TP Rs671; CMP Rs518):** ERIS has not been impacted by COVID led lockdown given 85% exposure to Chronic/Sub-Chronic segment. ERIS has been consistently outperforming the IPM when peer's growth has been in lower to mid-single-digit. Factors like benefit of MR's expansion and foray in new therapeutic are yet to play out in sales and headline margins, which could further lead to earnings growth. We assign 22x (PE) to FY23E and assume EPS CAGR of 10% over FY21-22E.


**INDOCO-BUY (TP Rs352; CMP Rs325):** INDR is poised to grow on better contributions from two key markets (US and India). Change in strategy for Indian market with more focus on chronic products with same MR count and launch of ophthalmic and oral ANDAs in partnerships in US are key growth drivers. EBITDAM to expand substantially and reach peer level due to lower regulatory cost. We value INDOCO on FY23E EPS of Rs20 and assign 18x(PE).

## India formulations fail to pick up even after marketing activities reach pre-COVID levels

- IPM growth in 3Q stands at 6.4%
- Selected companies like CIPLA, GNP, and CADILA continue to benefit from COVID led products.

India formulations growth had been impacted during lockdown as marketing activities were far below its normalized level, less number of new product launches and lower demand of acute products. With relaxations in lockdown norms and marketing activities reaching pre-COVID levels, most companies' core product growth (Ex-COVID related products) was in mid-single digit in 3QFY21 while ERIS life came out as an exception who significantly outperformed IPM even in lockdown.

Exhibit 3: Domestic Formulation Oct-Dec Gr %




Source: AIOCD, PL

**EBITDAM to remain flat QoQ for companies benefitting from COVID led products:** Most of the branded formulation players surprised with their earnings in 1QFY21 due to cost savings from less travelling and on-line promotional activities. Managements guided a part of their savings to be persistence for next few quarters and digital marketing becoming a theme. On an average, formulation players spend 22% of their revenue on SG&A. We believe EBITDAM to remain flat QoQ for few companies like **CIPLA, GNP and CADILA** as it would continue to benefit from COVID led products, which make savings in marketing/promotion and distribution costs. ERIS, SUNP and IPCA EBITDAM can decline 200-400bps as marketing activities reach pre-COVID levels without compensatory increase in revenues.

**Exhibit 4: EBITDAM to remain flat QoQ for companies benefitting from COVID products**

	Q4FY20	Q1FY21	Q2FY21	Q3FY21	QoQ EBITDAM chg(Bps)
<b>Cadila Healthcare</b>	<b>21.1</b>	<b>22.4</b>	<b>22.6</b>	<b>21.9</b>	<b>-0.7</b>
<b>Cipla</b>	<b>13.0</b>	<b>22.9</b>	<b>22.3</b>	<b>21.5</b>	<b>-0.8</b>
Dr. Reddy's Laboratories	21.4	25.3	25.1	25.4	0.3
Eris Lifesciences	29.8	34.3	36.9	35.0	-1.9
<b>Glenmark Pharmaceuticals</b>	<b>15.1</b>	<b>19.2</b>	<b>17.5</b>	<b>19.8</b>	<b>2.3</b>
Ipca Laboratories	19.2	39.6	27.8	23.5	-4.3
Lupin	12.4	12.4	14.0	15.7	1.7
Sun Pharmaceutical Industries	15.5	23.1	24.8	23.0	-1.8
Indoco Remedies	9.3	14.9	17.1	17.5	0.4
				<b>Avg</b>	<b>-0.5</b>

Source: Company, PL \* **Highlight companies to benefit from COVID products**




## US growth continues to remain muted

- Average QoQ growth in US biz has been only 1% (CC) in 12 quarters.
- Non-compliance of plants, issue of CRL (Complete Response Letter) and slower ramp up specialty products has led to muted growth.

While US generics/specialty contributes 36% of revenues in our coverage universe, it has been impacted with tepid average growth of 1% QoQ (12 quarters) led by non-compliance of plants, CRL (Complete Response Letter) and significant price erosion in core business. ARBP and CIPLA growth has been highest at 3% and 4% QoQ led by consistent ANDA approval for ARBP while CIPLA grew from the benefits of two limited competition drugs (gCinacalcet and gAlbuterol). US growth of LPC was only 0.27% due to regulatory issue of Goa and Pithampur-2 unit, underperformance of Gavis and slower ramp up in Solosec. SUNP and GNP growth is impacted due to rapid price erosion while regulatory issues impacted CADILA and DRRD.

**Exhibit 5: US QoQ average Gr (%) rate in last 12 quarters**



Source: Company, PL

We believe US growth over FY21-23E to be better with compliance issues set to fade away. Companies (with USFDA issues) mostly completed CAPA (Corrective and Preventive Actions) and are now awaiting USFDA inspection. Amongst our coverage, LPC, DRRD, SUNP and ARBP and CIPLA continue to grow better with diversified product portfolio, while CDH and GNP continue to underperform.

**Regulatory issue:** OAI status on Halol

**Key comments:** Global specialty products revenue were US\$108mn in 2QFY21. Hiked price of Ilumya by 5% recently.

**Key event in near-term:** Absorica conversion rate to lower dosage and Ilumya performance.

**Regulatory issue:** Goa, Pithampur (Indore) Unit-2, Mandideep-Unit I-API, Tarapur-API and Somerset under OAI/WL status.

**Key comments:** 8-10 complex injections in pipeline. Spiriva First to-File status and expected to launch in June-CY22.


**Key event in near-term:** gAlbuterol market share gain and volume of gMetformin XR after relaunch. FDAs action on plants with non-compliance.

**Regulatory issue:** Unit-I, IX, VII, XI and Aurolife under FDA scanner.

**Key comments:** Injectable revenue contribution to increase to US\$650-700m (v/s current US\$350m) in next 2-3 years and launch of one biosimilar in FY23E.


**Key event in near-term:** Re-inspection/virtual audit of plants under non-compliance

**Exhibit 6: SUNP Avg Gr 1% due to FDA issue and TARO price erosion**




Source: Company, PL

**Exhibit 7: LPC :Avg Gr (0.3%) due to FDA and GAVIS underperformance**



Source: Company, PL

**Exhibit 8: ARBP: Avg Gr 3% led by new approvals**



Source: Company, PL

**Regulatory issue:** Warning letter on Moraiya facility

**Key comments:** Guided for injectable revenue of US\$150mn in FY23E (v/s US\$15mn in FY20) with currently 30 injectables are under development. Current injectables are in a process of site transfer from Moraiya to Liva plant.

**Key event in near-term:** Competition in its key molecule Mesalamine which forms 30-35% of US revenue.

**Regulatory issue:** Warning letter on Goa Unit.


**Key comments:** Launch of one limited competition drug each quarter.

**Key event in near-term:** Market share gain in gAlbuterol(current share 10%) and FDAs action IV Tramadol CRL in Feb-Mar CY21.

**Key Comments:** DRRD revised its guidance upwards for number of launches in US to 30 products for FY21E v/s earlier 25. DRRD submitted its reply for gCopaxone while gRevlimid patent litigation has also been settled.


**Key event in near-term:** Launch of gVascepa and FDAs action on CRL for gCopaxone and gNuvaring.

**Exhibit 9: CADILA: Avg Gr 1% due to investment in specialty products**




Source: Company, PL

**Exhibit 10: CIPLA : Avg Gr 4% led by gAlbuterol and gCinacalcet**



Source: Company, PL

**Exhibit 11: DRRD: Avg Gr 1.5 % only due to regulatory issue in the past**




Source: Company, PL

**Regulatory issue:** Warning letter on Badi facility and CRL on Ryaltris

**Key comments:** Derma products (35% of US revenue) continues to witness price erosion of 15-20% due to competition in Mupirocin, Atomoxetine HCL and Calcipotriene

**Key event in near-term:** Announcement related to ICHNOS Sciences fund raising

**Exhibit 12: GNP: Avg de-growth 1.5 % due to price erosion in derma products**



Source: Company, PL

**Diagnostic companies to see growth in core biz (Ex-COVID testing):** Lockdown impacted core business of diagnostic companies in 1HFY21 while COVID testing was in focus during the same period. We believe core business to report growth of 5-10% YoY in 3Q due to pent up demand of bulk testing while COVID testing revenue to decline QoQ due to further price cut and lower numbers of new COVID cases in India.



**Exhibit 13: Q3FY21 Result Preview**

Company Name		Q3FY21E	Q3FY20	YoY gr. (%)	Q2FY21	QoQ gr. (%)	Remark
<b>Aurobindo Pharma</b>	Sales	66,980	57,994	15.5	63,779	5.0	Inj biz to revive gradually after COVID led lockdown impacted hospital biz with limited footfalls. The USFDA issues in Unit-I, IX, VII, XI and Aurolife remain unresolved. Apotex business to turn profitable from 2HFY21E along with an EBITDA margin for whole Europe business of 11-12% .
	EBITDA	13,999	11,125	25.8	13,273	5.5	
	Margin (%)	20.9	19.2		20.8		
	PBT	12,252	9,517	28.7	12,135	1.0	
	Adj. PAT	8,424	7,190	17.2	8,057	4.6	
<b>Cadila Healthcare</b>	Sales	38,323	36,381	5.3	38,200	0.3	Domestic frm growth to get held up due to launch of Remdesivir during the quarter while US(Gx) and ROW QoQ growth to be in lower single-digit.EBITDAM to decline marginally QoQ cause of benefit from Remdesivir launch.
	EBITDA	8,400	6,932	21.2	8,634	(2.7)	
	Margin (%)	21.9	19.1		22.6		
	PBT	6,339	4,587	38.2	6,662	(4.8)	
	Adj. PAT	5,146	3,739	37.6	4,734	8.7	
<b>Cipla</b>	Sales	48,840	42,346	15.3	49,726	(1.8)	Domestic(Branded+Generic+Consumer) growth to be in the range of 12-15% mainly led by COVID led products(Remdesivir+Actemra).US sales may remain flat QoQ to US\$135-140mn while SAGA could decline QoQ.
	EBITDA	10,501	6,219	68.9	11,109	(5.5)	
	Margin (%)	21.5	14.7		22.3		
	PBT	8,636	5,064	70.5	9,257	(6.7)	
	Adj. PAT	6,218	3,510	77.2	6,594	(5.7)	
<b>Dr. Lal PathLabs</b>	Sales	3,808	3,279	16.1	4,319	(11.8)	Core biz(Ex COVID) may witness growth in lower single-digit growth while COVID testing contribution to revenue could decline QoQ to below 10%(v/s due to 16% in Q2FY21) due to lower number of testing and further price cut.
	EBITDA	1,028	823	24.9	1,272	(19.2)	
	Margin (%)	27.0	25.1		29.5		
	PBT	919	734	25.2	1,166	(21.2)	
	Adj. PAT	689	541	27.4	871	(20.9)	
<b>Dr. Reddy's Laboratories</b>	Sales	49,373	43,971	12.3	49,109	0.5	India frm could see growth of 10%(inclusive of Wockardt) but its core portfolio has failed to pick up to its potential even after normalized activity of MRs. US (Gx) to remain muted due to delay in launch of gVascepa. EBITDAM to the best among comparable peers.
	EBITDA	12,532	10,313	21.5	12,342	1.5	
	Margin (%)	25.4	23.5		25.1		
	PBT	9,620	7,965	20.8	9,437	1.9	
	Adj. PAT	7,661	7,816	(2.0)	8,499	(9.9)	
<b>Eris Lifesciences</b>	Sales	3,121	2,618	19.2	3,253	(4.1)	Growth momentum to continue due to 80-85% revenue from chronic/sub-chronic products. ERIS continues to outperform the IPM on consistent basis. EBITDA YoY growth to be 52%(Adj 18%) cause of Rs180mn spend in 3QFY20 cause of Zomelis and new employees on board.
	EBITDA	1,093	722	51.5	1,200	(8.9)	
	Margin (%)	35.0	27.6		36.9		
	PBT	1,054	722	45.9	1,158	(9.0)	
	Adj. PAT	948	635	49.3	1,077	(12.0)	
<b>Glenmark Pharmaceuticals</b>	Sales	27,831	26,386	5.5	29,081	(4.3)	India Frm growth of double-digit to be led by Favipiravir while core portfolio continues to underperform IPM.US(Gx) lacks growth due to weak product pipeline while current derma products is witnessing significant price erosion.
	EBITDA	5,497	3,431	60.2	5,084	8.1	
	Margin (%)	19.8	13.0		17.5		
	PBT	3,472	2,710	28.1	3,362	3.3	
	Adj. PAT	2,431	1,908	27.4	2,277	6.7	
<b>Indoco Remedies</b>	Sales	3,336	2,834	17.7	3,225	3.4	Domestic frm(60-63% of revenue) could report flat to marginal negative due to revenue concentration on acute products. While all export segments to report growth. EBITDAM to be 17% as US contribution to increase.
	EBITDA	584	292	100.1	550	6.2	
	Margin (%)	17.5	10.3		17.1		
	PBT	387	113	243.0	362	6.8	
	Adj. PAT	271	93	191.2	251	7.9	
<b>Ipca Laboratories</b>	Sales	13,345	11,390	17.2	12,978	2.8	Domestic firm growth could in 5-7% while key growth driver would be API biz due to debottlenecking. Anti-malaria institutional biz to surpass its initial estimate of Rs2.5bn for FY21E.While EBITDAM would be 23-24% for 2HFY21E.
	EBITDA	3,136	2,654	18.2	3,602	(12.9)	
	Margin (%)	23.5	23.3		27.8		
	PBT	2,809	2,331	20.5	3,272	(14.1)	
	Adj. PAT	2,330	1,966	18.5	2,727	(14.6)	

Company Name		Q3FY21E	Q3FY20	YoY gr. (%)	Q2FY21	QoQ gr. (%)	Remark
<b>Jubilant Life Sciences</b>	Sales	25,553	23,152	10.4	23,749	7.6	
	EBITDA	5,081	5,074	0.1	4,862	4.5	Its key growth driver in pharma, Radiopharma products could see improved volume QoQ as turnout/visit of non-Covid patients in US hospitals witness gradual improvement.
	Margin (%)	19.9	21.9		20.5		
	PBT	3,840	3,280	17.1	3,137	22.4	
	Adj. PAT	2,735	2,380	14.9	2,242	22.0	
<b>Lupin</b>	Sales	38,896	37,161	4.7	37,818	2.9	US(Gx) could clock revenue of US\$190-195mn led by launch of Albuterol while domestic firm growth to be in lower single-digit. EBITDAM to improve QoQ on back of lower R&D spend.Q3FY20 had an impairment of the Gavis portfolio and divestiture of Kyowa.
	EBITDA	6,097	3,759	62.2	5,280	15.5	
	Margin (%)	15.7	10.1		14.0		
	PBT	4,518	1,809	149.8	3,598	25.6	
	Adj. PAT	3,180	-6,260	(150.8)	2,110	50.7	
<b>Sun Pharmaceutical Industries</b>	Sales	85,743	80,387	6.7	84,588	1.4	US(Taro+Gx+Specialty) growth to be lower single-digit even after improvement in Ilumya sales due to competition in its key drug Absorica. Domestic firm growth to remain tepid while EBITDAM to reduce QoQ due to normalized activities of MRs.
	EBITDA	19,735	16,434	20.1	20,989	(6.0)	
	Margin (%)	23.0	20.4		24.8		
	PBT	17,740	12,695	39.7	19,172	(7.5)	
	Adj. PAT	13,696	9,135	49.9	18,128	(24.4)	
<b>Thyrocare Technologies</b>	Sales	1,497	1,058	41.6	1,533	(2.3)	Core biz(Ex COVID) may witness growth of 10% due to pent up demand of bulk testing while COVID testing revenue to decline QoQ due to aggressive price by government.
	EBITDA	583	438	33.1	619	(5.7)	
	Margin (%)	38.9	41.4		40.4		
	PBT	529	364	45.1	589	(10.2)	
	Adj. PAT	408	275	48.2	430	(5.2)	

Source: Company, PL






Exhibit 14: Valuation Summary

Company Names	Rating	CMP (Rs)	TP (Rs)	Sales (Rs bn)				EBITDA (Rs bn)				PAT (Rs bn)				EPS (Rs)				RoE (%)				PE (x)			
				FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E	FY20	FY21E	FY22E	FY23E
Aurobindo Pharma	HOLD	945	920	227.4	259.6	284.1	304.4	45.0	53.8	61.5	65.9	28.3	33.5	37.7	41.4	48.3	57.1	64.4	70.7	18.4	18.3	17.6	16.4	19.6	16.6	14.7	13.4
Cadila Healthcare	Sell	485	357	138.1	153.1	160.9	170.6	23.4	34.8	36.9	35.8	11.8	19.9	20.8	20.3	11.5	19.5	20.4	19.8	11.3	19.9	20.0	16.8	42.3	24.9	23.8	24.5
Cipla	Acc	839	879	166.9	189.2	195.6	200.8	27.7	40.9	41.6	43.3	15.9	24.3	27.5	30.3	19.8	30.2	34.1	37.6	10.4	15.1	16.6	18.2	42.4	27.8	24.6	22.3
Dr. Lal PathLabs	UR	2,407	NA	13.3	14.6	15.4	17.7	3.4	3.8	4.2	4.8	2.3	2.5	2.8	3.2	27.0	30.2	33.7	39.0	22.8	23.3	22.6	21.9	89.0	79.7	71.4	61.7
Dr. Reddy's Lab.	BUY	5,338	5,975	167.7	192.0	221.7	240.4	34.0	47.0	54.3	60.7	26.1	28.7	35.1	40.2	157.2	172.6	207.9	238.0	17.6	17.2	18.2	18.0	34.0	30.9	25.7	22.4
Eris Lifesciences	BUY	619	671	10.6	12.0	13.5	15.1	3.5	4.2	4.5	4.8	3.0	3.6	3.8	4.2	21.9	26.7	28.3	30.9	24.3	28.0	30.3	34.1	28.3	23.2	21.9	20.0
Glenmark Pharma	Sell	518	449	104.0	108.8	122.8	136.0	14.5	19.1	18.8	18.0	7.8	9.0	9.8	10.6	27.5	32.0	34.9	37.4	13.3	13.9	13.3	12.6	18.8	16.2	14.8	13.8
Indoco Remedies	BUY	325	352	10.8	12.4	15.3	17.5	1.0	2.0	2.4	2.8	0.2	1.0	1.4	1.8	2.6	10.9	15.7	19.6	3.6	14.6	18.6	18.9	123.6	29.8	20.7	16.6
Ipca Laboratories	Acc	2,143	2,413	46.5	52.5	58.1	67.7	9.1	15.4	13.5	16.0	6.0	11.5	9.5	11.3	47.8	91.1	75.1	89.4	17.9	27.8	18.6	18.7	44.9	23.5	28.6	24.0
Jubilant Life Sciences	Acc	929	964	89.8	98.1	100.1	117.1	17.7	18.1	17.8	22.1	9.0	8.6	9.0	12.1	56.2	54.3	56.6	76.0	17.2	14.4	13.2	15.4	16.5	17.1	16.4	12.2
Lupin	BUY	1,039	1,214	151.4	156.3	187.5	215.0	21.2	24.0	39.1	44.0	3.5	10.2	20.5	22.9	7.8	22.6	45.2	50.5	2.7	8.1	15.0	14.8	133.8	46.1	23.0	20.6
Sun Pharma Ind.	HOLD	621	602	323.3	327.6	380.7	409.2	64.8	78.9	91.4	98.0	35.8	63.0	64.0	68.8	14.9	26.2	26.7	28.7	8.3	15.2	15.8	14.8	41.6	23.7	23.3	21.7
Thyrocare Tech.	UR	970	NA	4.3	5.1	6.2	6.6	1.7	1.9	2.5	2.7	0.9	1.2	1.7	1.8	16.7	23.6	32.4	33.6	22.0	29.1	30.4	24.9	58.0	41.1	29.9	28.9

Source: Company, PL

UR = Under Review

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aurobindo Pharma	Accumulate	921	840
2	Cadila Healthcare	Sell	357	411
3	Cipla	BUY	887	756
4	Dr. Lal PathLabs	UR	-	2,179
5	Dr. Reddy's Laboratories	BUY	5,964	4,951
6	Eris Lifesciences	BUY	671	518
7	Glenmark Pharmaceuticals	Sell	424	481
8	Indoco Remedies	BUY	352	256
9	Ipca Laboratories	Hold	2,393	2,278
10	Jubilant Life Sciences	Accumulate	752	696
11	Lupin	BUY	1,212	936
12	Sun Pharmaceutical Industries	BUY	597	486
13	Thyrocare Technologies	UR	-	1,138

**PL's Recommendation Nomenclature**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly

## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

---

## **Prabhudas Lilladher Pvt. Ltd.**

**3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209**

[www.plindia.com](http://www.plindia.com)